Related Experiment Video
Updated: Sep 4, 2025
08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
21.2K
Therapeutic Outcomes in High-Grade B-Cell Lymphoma, NOS: Retrospective Analysis.
Parathan Karunakaran1, Gangothri Selvarajan1, Jayachandran Perumal Kalaiyarasi1
1Department of Medical Oncology, Cancer Institute (WIA), Chennai, India.
South Asian Journal of Cancer
|July 14, 2022
Summary
High-grade B cell lymphoma, not otherwise specified (HGBL, NOS) treatment and prognosis were analyzed. The National Comprehensive Cancer Network-International Prognostic Index (NCCN-IPI) significantly influenced outcomes, suggesting tailored therapy may be beneficial.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- High-grade non-Hodgkin's lymphoma nomenclature changed to high-grade B cell lymphoma (HGBL) in the 2016 WHO update.
- High-grade B cell lymphoma, not otherwise specified (HGBL, NOS) is poorly characterized regarding treatment and prognosis.
Purpose of the Study:
- To analyze baseline characteristics, treatment, and outcomes of HGBL, NOS patients.
- To evaluate prognostic factors, including the NCCN-IPI, for HGBL, NOS.
Main Methods:
- Retrospective analysis of 30 HGBL, NOS patients diagnosed between January 2017 and December 2019.
- Assessment of patient demographics, International Prognostic Index (IPI), chemotherapy regimens (R-CHOP, R-EPOCH), and follow-up data.
- Evaluation of event-free survival (EFS) and overall survival (OS) in relation to prognostic scores.
Main Results:
- Median patient age was 49.3 years, with 30% having advanced IPI.
- Most patients received R-CHOP chemotherapy; nine experienced disease progression or relapse at 15 months median follow-up.
- Event-free survival (EFS) was 22 months and overall survival (OS) was 37 months. Only NCCN-IPI ≤ 2 significantly impacted outcomes.
Conclusions:
- The NCCN-IPI is crucial for determining HGBL, NOS prognosis.
- More intensive chemotherapy may be beneficial for HGBL, NOS.
- Prospective trials are needed to confirm if NCCN-IPI can guide personalized treatment strategies for HGBL, NOS.
